ID

35145

Beschreibung

A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02392507

Link

https://clinicaltrials.gov/show/NCT02392507

Stichworte

Versionen (1)
  1. 19.02.19 19.02.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

19. Februar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Carcinoma, Non-small-Cell Lung NCT02392507

Englisch

Eligibility Carcinoma, Non-small-Cell Lung NCT02392507

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
have histologically or cytologically confirmed squamous nsclc.
Beschreibung

Squamous non-small cell lung cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C4509816
have stage iv disease at the time of study entry (american joint committee on cancer [ajcc] staging manual, 7th edition).
Beschreibung

Disease TNM clinical staging

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C3258246
have measurable disease at the time of study enrollment as defined by response evaluation criteria in solid tumors, version 1.1 (recist 1.1).
Beschreibung

Measurable Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C1513041
have tumor tissue available for biomarker analysis.
Beschreibung

Availability of Tumor tissue sample | Biomarker Analysis

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C0475358
UMLS CUI [2,1]
C0005516
UMLS CUI [2,2]
C0002778
have an eastern cooperative oncology group (ecog) performance status of 0 to 1.
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
have adequate organ functions.
Beschreibung

Organ function

Datentyp

boolean

Alias
UMLS CUI [1]
C0678852
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
are currently enrolled in another clinical trial.
Beschreibung

Study Subject Participation Status

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
have received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the epidermal growth factor receptor (egfr), vascular endothelial growth factor (vegf), or vegf receptor.
Beschreibung

Cancer treatment | Monoclonal Antibodies | Signal Transduction Inhibitor | Therapy Targeting Epidermal Growth Factor Receptor | Therapy Targeting Vascular Endothelial Growth Factors | Therapy Targeting Vascular Endothelial Growth Factor Receptor

Datentyp

boolean

Alias
UMLS CUI [1]
C0920425
UMLS CUI [2]
C0003250
UMLS CUI [3]
C1519313
UMLS CUI [4,1]
C0087111
UMLS CUI [4,2]
C1521840
UMLS CUI [4,3]
C0034802
UMLS CUI [5,1]
C0087111
UMLS CUI [5,2]
C1521840
UMLS CUI [5,3]
C1256770
UMLS CUI [6,1]
C0087111
UMLS CUI [6,2]
C1521840
UMLS CUI [6,3]
C0148199
have received previous chemotherapy for advanced nsclc. participants who have received adjuvant or neoadjuvant chemotherapy are eligible if the last administration of the prior regimens occurred at least 1 year prior to study entry.
Beschreibung

Prior Chemotherapy Non-Small Cell Lung Carcinoma Advanced

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0007131
UMLS CUI [1,3]
C0205179
have undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.
Beschreibung

Major surgery | Therapies, Investigational

Datentyp

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C0949266
have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.
Beschreibung

Therapeutic radiology procedure Systemic | Therapeutic radiology procedure Focal

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0205373
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0205234
have symptomatic central nervous system (cns) malignancy or metastasis (screening not required).
Beschreibung

Malignant Central Nervous System Neoplasm Symptomatic | CNS metastases Symptomatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0348374
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
have a history of arterial or venous embolism within 6 months prior to study entry.
Beschreibung

Arterial embolism | Venous embolism

Datentyp

boolean

Alias
UMLS CUI [1]
C0549124
UMLS CUI [2]
C0340726
have clinical evidence of concomitant infectious conditions.
Beschreibung

Communicable/infectious condition

Datentyp

boolean

Alias
UMLS CUI [1]
C1948090
have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.
Beschreibung

Hypersensitivity Therapeutic procedure Component | Allergic Reaction Therapeutic procedure Component | Hypersensitivity Necitumumab Ingredient | Allergic Reaction Necitumumab Ingredient | Medical contraindication Therapeutic procedure

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C1705248
UMLS CUI [2,1]
C1527304
UMLS CUI [2,2]
C0087111
UMLS CUI [2,3]
C1705248
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C2352806
UMLS CUI [3,3]
C1550600
UMLS CUI [4,1]
C1527304
UMLS CUI [4,2]
C2352806
UMLS CUI [4,3]
C1550600
UMLS CUI [5,1]
C1301624
UMLS CUI [5,2]
C0087111
are pregnant or breastfeeding.
Beschreibung

Pregnancy | Breast Feeding

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
have a known history of drug abuse.
Beschreibung

Drug abuse

Datentyp

boolean

Alias
UMLS CUI [1]
C0013146
have a concurrent active malignancy. participants with a history of malignancy are eligible provided the participant has been disease-free for ≥3 years, with the following exception: participants with adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the judgment of the investigator and lilly clinical research physician/designee may not affect the interpretation of results (for example, prostate, bladder) are eligible.
Beschreibung

Cancer Other | Exception Disease Free Duration | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix | Exception Prostate carcinoma | Exception Carcinoma of bladder

Datentyp

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0012634
UMLS CUI [2,3]
C0332296
UMLS CUI [2,4]
C0449238
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0553723
UMLS CUI [4,3]
C1522326
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0851140
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0600139
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0699885
have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.
Beschreibung

Investigational New Drug Discontinued | Study Subject Participation Status | Investigational New Drugs | Investigational Medical Device

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C1444662
UMLS CUI [2]
C2348568
UMLS CUI [3]
C0013230
UMLS CUI [4]
C2346570
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Carcinoma, Non-small-Cell Lung NCT02392507

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Squamous non-small cell lung cancer
Item
have histologically or cytologically confirmed squamous nsclc.
boolean
C4509816 (UMLS CUI [1])
Disease TNM clinical staging
Item
have stage iv disease at the time of study entry (american joint committee on cancer [ajcc] staging manual, 7th edition).
boolean
C0012634 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
Measurable Disease
Item
have measurable disease at the time of study enrollment as defined by response evaluation criteria in solid tumors, version 1.1 (recist 1.1).
boolean
C1513041 (UMLS CUI [1])
Availability of Tumor tissue sample | Biomarker Analysis
Item
have tumor tissue available for biomarker analysis.
boolean
C0470187 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
C0005516 (UMLS CUI [2,1])
C0002778 (UMLS CUI [2,2])
ECOG performance status
Item
have an eastern cooperative oncology group (ecog) performance status of 0 to 1.
boolean
C1520224 (UMLS CUI [1])
Organ function
Item
have adequate organ functions.
boolean
C0678852 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status
Item
are currently enrolled in another clinical trial.
boolean
C2348568 (UMLS CUI [1])
Cancer treatment | Monoclonal Antibodies | Signal Transduction Inhibitor | Therapy Targeting Epidermal Growth Factor Receptor | Therapy Targeting Vascular Endothelial Growth Factors | Therapy Targeting Vascular Endothelial Growth Factor Receptor
Item
have received prior anticancer therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the epidermal growth factor receptor (egfr), vascular endothelial growth factor (vegf), or vegf receptor.
boolean
C0920425 (UMLS CUI [1])
C0003250 (UMLS CUI [2])
C1519313 (UMLS CUI [3])
C0087111 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C0034802 (UMLS CUI [4,3])
C0087111 (UMLS CUI [5,1])
C1521840 (UMLS CUI [5,2])
C1256770 (UMLS CUI [5,3])
C0087111 (UMLS CUI [6,1])
C1521840 (UMLS CUI [6,2])
C0148199 (UMLS CUI [6,3])
Prior Chemotherapy Non-Small Cell Lung Carcinoma Advanced
Item
have received previous chemotherapy for advanced nsclc. participants who have received adjuvant or neoadjuvant chemotherapy are eligible if the last administration of the prior regimens occurred at least 1 year prior to study entry.
boolean
C1514457 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0205179 (UMLS CUI [1,3])
Major surgery | Therapies, Investigational
Item
have undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.
boolean
C0679637 (UMLS CUI [1])
C0949266 (UMLS CUI [2])
Therapeutic radiology procedure Systemic | Therapeutic radiology procedure Focal
Item
have undergone systemic radiotherapy within 4 weeks prior to study entry, or focal radiotherapy within 2 weeks prior to study entry.
boolean
C1522449 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0205234 (UMLS CUI [2,2])
Malignant Central Nervous System Neoplasm Symptomatic | CNS metastases Symptomatic
Item
have symptomatic central nervous system (cns) malignancy or metastasis (screening not required).
boolean
C0348374 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Arterial embolism | Venous embolism
Item
have a history of arterial or venous embolism within 6 months prior to study entry.
boolean
C0549124 (UMLS CUI [1])
C0340726 (UMLS CUI [2])
Communicable/infectious condition
Item
have clinical evidence of concomitant infectious conditions.
boolean
C1948090 (UMLS CUI [1])
Hypersensitivity Therapeutic procedure Component | Allergic Reaction Therapeutic procedure Component | Hypersensitivity Necitumumab Ingredient | Allergic Reaction Necitumumab Ingredient | Medical contraindication Therapeutic procedure
Item
have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.
boolean
C0020517 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C1527304 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
C0020517 (UMLS CUI [3,1])
C2352806 (UMLS CUI [3,2])
C1550600 (UMLS CUI [3,3])
C1527304 (UMLS CUI [4,1])
C2352806 (UMLS CUI [4,2])
C1550600 (UMLS CUI [4,3])
C1301624 (UMLS CUI [5,1])
C0087111 (UMLS CUI [5,2])
Pregnancy | Breast Feeding
Item
are pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Drug abuse
Item
have a known history of drug abuse.
boolean
C0013146 (UMLS CUI [1])
Cancer Other | Exception Disease Free Duration | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix | Exception Prostate carcinoma | Exception Carcinoma of bladder
Item
have a concurrent active malignancy. participants with a history of malignancy are eligible provided the participant has been disease-free for ≥3 years, with the following exception: participants with adequately treated basal or squamous cell carcinoma of the skin, preinvasive carcinoma of the cervix, or any cancer that in the judgment of the investigator and lilly clinical research physician/designee may not affect the interpretation of results (for example, prostate, bladder) are eligible.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0332296 (UMLS CUI [2,3])
C0449238 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0851140 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0600139 (UMLS CUI [6,2])
C1705847 (UMLS CUI [7,1])
C0699885 (UMLS CUI [7,2])
Investigational New Drug Discontinued | Study Subject Participation Status | Investigational New Drugs | Investigational Medical Device
Item
have discontinued investigational product or non approved use of a drug or device from a clinical trial within 30 days before the first day of study treatment.
boolean
C0013230 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C2348568 (UMLS CUI [2])
C0013230 (UMLS CUI [3])
C2346570 (UMLS CUI [4])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video